Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 5,547 matching trials from the live ClinicalTrials.gov search.
Filters: Sacramento, California Clear all
Completed Phase 2Phase 3 Interventional Results available

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

NCT01580293
View directory record Official record
Conditions
Hemophilia A
Interventions
BAY94-9027
Biological
Lead sponsor
Bayer
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
14
States / cities
Tucson, Arizona • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies

NCT00142298
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Telbivudine (LdT)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
16 Years to 70 Years
Enrollment
1,869 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • Pasadena, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Phase 3 Interventional

A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients

NCT00002406
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Phase 3 Interventional

Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer

NCT00083304
View directory record Official record
Conditions
Breast Cancer, Metastases
Interventions
Efaproxiral, Whole Brain Radiation Therapy (WBRT), Supplemental Oxygen
Drug · Radiation · Other
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

NCT01968733
View directory record Official record
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Moxifloxacin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
62
States / cities
Mobile, Alabama • Little Rock, Arkansas • Chino, California + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 28, 2026, 4:38 PM EDT
Recruiting Not applicable Interventional

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

NCT04251052
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, Ultrasound Imaging
Procedure · Other
Lead sponsor
NRG Oncology
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
1,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2047
U.S. locations
564
States / cities
Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 372 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Not applicable Interventional

Feasibility of Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic, Severe Aortic Stenosis

NCT02628899
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Transfemoral TAVR, SAVR
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
Not listed
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
11
States / cities
Sacramento, California • San Diego, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

NCT01780506
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
78
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Phase 2 Interventional

S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00003416
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, recombinant interferon alfa, dexamethasone, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 69 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma

NCT02194699
View directory record Official record
Conditions
Uncontrolled Asthma
Interventions
Experimental: Tralokinumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
82
States / cities
Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

NCT02565914
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Phase 4 Interventional Results available

VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2

NCT00306293
View directory record Official record
Conditions
Herpes Labialis
Interventions
valacyclovir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
18
States / cities
Anaheim, California • Carmichael, California • Fair Oaks, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Phase 2 Interventional Results available

Ganaxolone Treatment in Children With Fragile X Syndrome

NCT01725152
View directory record Official record
Conditions
Fragile x Syndrome
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Not applicable Interventional

Set-back Suture Versus Traditional Vertical Mattress Suture

NCT01773447
View directory record Official record
Conditions
Basal Cell Carcinoma, Squamous Cell Carcinoma, Melanoma
Interventions
Set-back suture, Vertical mattress suture
Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure

NCT00303498
View directory record Official record
Conditions
Diastolic Heart Failure
Interventions
Sitexsentin sodium, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Alaska + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison Of Video-based Versus Written Patient Education on Sunscreen

NCT00826306
View directory record Official record
Conditions
Dermatology Disease, Skin Cancer
Interventions
Patient Educational Materials
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT04195698
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
33
States / cities
Little Rock, Arkansas • Fountain Valley, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Not applicable Interventional Results available

XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.

NCT03218787
View directory record Official record
Conditions
Coronary Artery Lesions
Interventions
XIENCE, DAPT
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
101
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 88 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 28, 2026, 4:38 PM EDT
Enrolling by invitation Phase 3 Interventional

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT04905693
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
Interventions
Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
Drug · Device
Lead sponsor
United Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
1,850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
81
States / cities
Birmingham, Alabama • Franklin, Arizona • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 4:38 PM EDT
Recruiting Not applicable Interventional

I-DECIDE After Bronchiolitis Hospitalization

NCT07243652
View directory record Official record
Conditions
Bronchiolitis Acute
Interventions
Moderate-Resource Implementation Strategy, High-Resource Implementation Strategy
Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
0 Months to 24 Months
Enrollment
2,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
60
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Phase 3 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)

NCT03244644
View directory record Official record
Conditions
Clostridium Difficile Infection (CDI)
Interventions
RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence)
Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
60
States / cities
Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 28, 2026, 4:38 PM EDT
Terminated Phase 3 Interventional

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

NCT01836432
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
Interventions
FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation, Gemcitabine, Capecitabine, Nab-Paclitaxel
Drug · Biological · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
32
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 28, 2026, 4:38 PM EDT
Active, not recruiting Phase 2 Interventional

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

NCT03609216
View directory record Official record
Conditions
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
Interventions
Gemcitabine Hydrochloride, Cisplatin, Pegfilgrastim, Conventional Surgery, Radical Cystectomy, Chemoradiotherapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
424
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 293 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 4:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit

NCT02863809
View directory record Official record
Conditions
Keratolysis
Interventions
Riboflavin, Dextran, UVA Light Source
Drug · Device
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 28, 2026, 4:38 PM EDT